Novavax (NASDAQ:NVAX) Stock Price Expected to Rise, HC Wainwright Analyst Says

Novavax (NASDAQ:NVAX) had its price target raised by research analysts at HC Wainwright from $11.00 to $16.00 in a research note issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target points to a potential upside of 42.98% from the company’s previous close.

A number of other equities analysts have also recently issued reports on the stock. B. Riley Financial restated a “buy” rating and issued a $16.00 price objective (down from $18.00) on shares of Novavax in a research report on Monday, November 10th. Weiss Ratings reissued a “sell (d+)” rating on shares of Novavax in a research note on Monday, December 29th. Wall Street Zen downgraded Novavax from a “hold” rating to a “sell” rating in a report on Saturday, January 31st. TD Cowen lowered their price target on Novavax from $8.00 to $7.00 and set a “hold” rating for the company in a research report on Tuesday, November 4th. Finally, BTIG Research reiterated a “buy” rating and issued a $19.00 price objective on shares of Novavax in a report on Tuesday, January 20th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat, Novavax currently has an average rating of “Hold” and a consensus target price of $11.88.

Novavax Trading Up 17.4%

Shares of NVAX opened at $11.19 on Friday. Novavax has a fifty-two week low of $5.01 and a fifty-two week high of $11.97. The firm has a market cap of $1.82 billion, a price-to-earnings ratio of 6.25 and a beta of 2.58. The firm has a 50 day moving average price of $8.27 and a 200-day moving average price of $8.02. The company has a debt-to-equity ratio of 5.93, a quick ratio of 2.24 and a current ratio of 2.27.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.77. Novavax had a negative return on equity of 217.02% and a net margin of 32.10%.The business had revenue of $136.40 million for the quarter, compared to analyst estimates of $90.26 million. During the same period last year, the company earned ($0.51) EPS. Novavax’s revenue for the quarter was up 66.6% compared to the same quarter last year. As a group, equities research analysts forecast that Novavax will post -1.46 earnings per share for the current year.

Hedge Funds Weigh In On Novavax

Several institutional investors and hedge funds have recently modified their holdings of NVAX. Flagship Harbor Advisors LLC bought a new stake in shares of Novavax during the fourth quarter valued at approximately $33,000. Quarry LP purchased a new stake in shares of Novavax in the 3rd quarter worth $33,000. State of Wyoming purchased a new stake in Novavax in the second quarter worth about $52,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Novavax by 25.8% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,896 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 1,617 shares in the last quarter. Finally, Danske Bank A S purchased a new stake in Novavax in the 3rd quarter worth approximately $64,000. 53.04% of the stock is currently owned by institutional investors.

Key Stories Impacting Novavax

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Q4 beat and surprise profit: Novavax posted Q4 revenue well above estimates and reported GAAP EPS of $0.11 (vs. consensus losses), delivering a surprise quarterly profit that lifted investor confidence. Article Title
• Positive Sentiment: Raised 2026 adjusted revenue outlook tied to vaccine deals and expected milestone payments — management says milestone/licensing receipts should offset weaker underlying demand, supporting near‑term cash flow visibility. Article Title
• Positive Sentiment: Operational strength and balance sheet: Full-year 2025 revenue of ~$1.1B, $225M in Sanofi milestone payments recognized in 2025, year-end cash of ~$751M, and announced cost/reduction targets achieved — all reduce near-term financing risk. Article Title
• Positive Sentiment: Partnerships/licensing progress: New non‑exclusive Matrix‑M license with Pfizer announced and multiple material transfer agreements with major pharma firms signal broader commercial interest in Novavax’s adjuvant and potential new revenue streams. Article Title
• Neutral Sentiment: Management outreach: Novavax will participate in investor conferences (TD Cowen fireside chat Mar. 3), which provides more disclosure and Q&A opportunities but is informational rather than fundamentally changing. Article Title
• Neutral Sentiment: Earnings call transcript available — read management commentary for detail on 2026 assumptions and product demand dynamics. Article Title
• Neutral Sentiment: Unusual options activity: A large increase in call option volume suggests short-term bullish/speculative positioning by traders, which can amplify intraday moves (no linked article).
• Negative Sentiment: Conservative FY2026 revenue guidance vs. street expectations: While management raised an adjusted outlook tied to milestone receipts, the explicit FY2026 revenue guidance range is materially below consensus, creating uncertainty about organic demand trends and generating mixed investor reactions. Article Title

Novavax Company Profile

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.